AdjuTec Pharma AS

AdjuTec Pharma’s Lead Product APC301 Shows Superior Activity in Multidrug-Resistant High-risk Pathogens

Oslo, Norway, 2 March 2026 – AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, today announces positive preclinical results from studies in multidrug-resistant (MDR) pathogens with its lead product APC301. The results strongly support ongoing clinical development of APC301 including its unique enzyme inhibitor technology
APC301, a clinical stage combination antibiotic, was tested in vitro and in vivo in three studies to verify previous positive results in MDR pathogens (Enterobacterales). APC301 targets high-risk pathogens that produce enzymes, namely MBLs and SBLs, that destroy last-resort antibiotics like meropenem. In an in vitro susceptibility study APC301 was tested in a global collection of 176 MDR MBL-producing Enterobacterales and compared to state-of-art antibiotics. APC301 performed better than all comparators with 100% susceptibility in all 131 E. coli and K. pneumoniae isolates.

In a follow-up study AdjuTec Pharma, in collaboration with Venus Remedies, performed an in vitro susceptibility study in an Indian collection of 303 MBL-producing Enterobacterales. The results confirmed a successful activity in >97% of the pathogens including E. coli and K. pneumoniae.

To verify the in vitro susceptibility studies AdjuTec Pharma’s has conducted in vivo studies which are intended to support the clinical program in patients with serious infections caused by these pathogens. Recent in vivo studies further supported the in vitro activity of APC301 in meropenem resistant Enterobacterales.

The in vitro results will be presented by AdjuTec Pharma at the AMR Conference in Basel 3-4 March 2026.
AdjuTec Pharma AS, COO, Bjørn Klem said:
“MBL-producing pathogens is spreading globally at an alarming rate and is a huge problem for clinicians with hardly any effective modern antibiotics to choose from. These preclinical results provide clear evidence that our new MBL-inhibitor technology can be of immense value in combination with last-resort antibiotics.

APC301 combines meropenem with state-of-art enzyme inhibitor technology but combinations with cephalosporins are similarly encouraging. As carbapenems and cephalosporins target large markets with unserved medical needs, AdjuTec Pharma will be well positioned to address treatment of patients with multidrug-resistant pathogens like Enterobacterales”

About antimicrobial resistance (AMR)

https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

About AdjuTec Pharma AS

AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company´s technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The company is located at ShareLab(Oslo Science Park), Gaustadalléen 21 - downtown Oslo.

For more information, please visit www.adjutecpharma.com or contact us at info@adjutecpharma.com
2026-03-02 01:27